Sirona Biochem Announces License Agreement with Cincinnati Children's Hospital Medical Center
January 15 2014 - 7:45AM
Marketwired
Sirona Biochem Announces License Agreement with Cincinnati
Children's Hospital Medical Center
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 15, 2014) -
Sirona Biochem Corp.
(TSX-VENTURE:SBM)(OTCQX:SRBCF) and Cincinnati Children's Hospital
Medical Center announce the formalization of a license agreement of
Cincinnati Children's patented synthetic vernix technology.
Sirona Biochem plans to create an anti-aging skin care treatment
that combines their patented cell preservation glycoprotein with
Cincinnati Children's technology.
Sirona will lead the development, with support from Cincinnati
Children's, of the anti-aging cream incorporating the proprietary
technologies of each organization. The resulting new anti-aging
product will be patented with the goal of licensing the new
technology to a global leader in the cosmetic and consumer packaged
good marketplaces.
It is expected by both Sirona and Cincinnati Children's that new
patents and applications (cosmetic and therapeutic) for this
combined technology may be discovered and the collaboration is
structured to support the goal of future commercial revenue from
multiple sources.
"We are proud to be working in partnership with Cincinnati
Children's Hospital Medical Center, a world leader in patient care
and breakthrough research," said Neil Belenkie, CEO of Sirona
Biochem. "Our shared goal is to create an anti-aging skin treatment
that presents unparalleled efficacy and commercial opportunity for
the predicted $300 billion dollar anti-aging global market."
"We are excited to formalize this agreement with Sirona Biochem
and look forward to continuing to work together," said Niki
Robinson, PhD, assistant vice president of Cincinnati Children's
Center for Technology Commercialization.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary technology platform developed at its
laboratory facility in France. The company specializes in the
stabilization of carbohydrate molecules, with the goal of improving
compounds' efficacy and safety. Sirona Biochem's compounds are
patented as new chemical entities for maximum commercial protection
and revenue potential. Newly developed compounds are licensed to
leading companies around the world in return for licensing and
milestone fees and ongoing royalty payments. TFChem, Sirona
Biochem's wholly-owned French laboratory is a recipient of multiple
French national scientific awards and a European Union and French
government grant. For more information visit
www.sironabiochem.com.
About Cincinnati Children's Hospital Medical Center
Cincinnati Children's Hospital Medical Center ranks third in the
nation among all Honor Roll hospitals in U.S. News and World
Report's 2013 Best Children's Hospitals ranking. It is ranked #1
for cancer and in the top 10 for nine of 10 pediatric specialties.
Cincinnati Children's, a non-profit organization, is one of the top
three recipients of pediatric research grants from the National
Institutes of Health, and a research and teaching affiliate of the
University of Cincinnati College of Medicine. The medical center is
internationally recognized for improving child health and
transforming delivery of care through fully integrated, globally
recognized research, education and innovation. Additional
information can be found at www.cincinnatichildrens.org. Connect on
the Cincinnati Children's blog, via Facebook and on Twitter.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
Sirona Biochem Corp.Christopher
HoptonCFO1.604.282.6064chopton@sironabiochem.comwww.sironabiochem.com
Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Jul 2023 to Jul 2024